Related Experiment Video
Updated: Nov 7, 2025
Preparation of Adipose Progenitor Cells from Mouse Epididymal Adipose Tissues
Published on: August 25, 2020
Establishment of a Pediatric Ovarian and Testicular Cryopreservation Program for Malignant and Non-Malignant
Vidhu B Joshi1, Supriya Behl2, Siobhan T Pittock3
1Department of Urology, Mayo Clinic, Rochester, Minnesota.
Study Objectives:
To describe the structure of a pediatric fertility preservation (FP) program and to share safety and patient satisfaction data.
Design:
The FP program operates under prospective research protocols approved by the Mayo Clinic Institutional Review Board (IRB).
Setting:
The FP program is a multidisciplinary effort between pediatric gynecology, reproductive endocrinology, pediatric urology, pediatric surgery, and laboratory medicine.
Participants:
The FP program enrolls patients between 0-17 years of age who have been diagnosed with a fertility-threatening condition and/or are scheduled to undergo gonadotoxic treatment.
Interventions:
FP is offered in the form of ovarian tissue cryopreservation (OTC) and testicular (TTC) tissue cryopreservation.
Main Outcome Measures:
The outcome measures are the safety of the procedure and results of patient surveys conducted by phone using a standard list of questions to assess attitudes towards FP.
Results:
To date, we have enrolled 38 OTC and 37 TTC patients. The median age (range) of OTC and TTC patients was 11 years (0.83-17 years) and 10 years (0.92-17 years) at the time of enrollment, respectively. Childhood cancers currently represent 88% of the fertility-threatening diagnoses. Meanwhile, patients with non-malignant conditions include those with gender dysphoria, aplastic anemia, and Turner's syndrome. To date, no serious adverse events (SAEs) have been reported following surgery. According to n = 34 one-year follow-ups, 100% of parents felt that FP was a good decision.
Conclusion:
Consistent with the literature, our data suggests FP is safe and improves the quality of care provided to pediatric patients for their fertility-threatening diagnoses and/or treatments.
Trial Registration:
NCT02872532, NCT02646384.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023